Zhu C, Yang J, Liu L, Li B, Sun T, Sheng W
Discov Oncol. 2025; 16(1):34.
PMID: 39800812
PMC: 11725561.
DOI: 10.1007/s12672-025-01790-2.
Li L, Cheng S, Yeh Y, Shi Y, Henderson N, Price D
Front Oncol. 2024; 14:1392085.
PMID: 38680860
PMC: 11045992.
DOI: 10.3389/fonc.2024.1392085.
Li L, Cheng S, Yeh Y, Shi Y, Henderson N, Price D
bioRxiv. 2024; .
PMID: 38260443
PMC: 10802256.
DOI: 10.1101/2023.09.27.559832.
Zhan L, Su F, Li Q, Wen Y, Wei F, He Z
Front Pharmacol. 2023; 14:1257450.
PMID: 37693915
PMC: 10484417.
DOI: 10.3389/fphar.2023.1257450.
Ercan H, Resch U, Hsu F, Mitulovic G, Bileck A, Gerner C
Cells. 2023; 12(5).
PMID: 36899884
PMC: 10000902.
DOI: 10.3390/cells12050747.
Construction of Glycolytic Regulator Gene Signature to Predict the Prognosis and Tumor Immune Cell Infiltration Levels for Prostate Cancer.
Zhang L, Wang B, Wang Z, Guo Y, Shen H
Comput Math Methods Med. 2022; 2022:9273559.
PMID: 35242214
PMC: 8888065.
DOI: 10.1155/2022/9273559.
Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets.
Marima R, Hull R, Mathabe K, Setlai B, Batra J, Sartor O
Am J Cancer Res. 2021; 11(4):1012-1030.
PMID: 33948343
PMC: 8085879.
Increased expression of glycolytic enzymes in prostate cancer tissues and association with Gleason scores.
Wang J, Li J, Li X, Peng S, Li J, Yan W
Int J Clin Exp Pathol. 2020; 10(11):11080-11089.
PMID: 31966456
PMC: 6965816.
Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jimenez-Vacas J, Herrero-Aguayo V, Montero-Hidalgo A, Gomez-Gomez E, Fuentes-Fayos A, Leon-Gonzalez A
EBioMedicine. 2020; 51:102547.
PMID: 31902674
PMC: 7000340.
DOI: 10.1016/j.ebiom.2019.11.008.
Prostate Cancer Energetics and Biosynthesis.
Lin C, Salzillo T, Bader D, Wilkenfeld S, Awad D, Pulliam T
Adv Exp Med Biol. 2020; 1210:185-237.
PMID: 31900911
PMC: 8096614.
DOI: 10.1007/978-3-030-32656-2_10.
Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane.
Singh K, Hahm E, Alumkal J, Foley L, Hitchens T, Shiva S
Carcinogenesis. 2019; 40(12):1545-1556.
PMID: 31555797
PMC: 7175465.
DOI: 10.1093/carcin/bgz155.
Shmt2: A Stat3 Signaling New Player in Prostate Cancer Energy Metabolism.
Marrocco I, Altieri F, Rubini E, Paglia G, Chichiarelli S, Giamogante F
Cells. 2019; 8(9).
PMID: 31500219
PMC: 6770108.
DOI: 10.3390/cells8091048.
Silencing of carbonic anhydrase I enhances the malignant potential of exosomes secreted by prostatic tumour cells.
Banova Vulic R, Zduriencikova M, Tyciakova S, Benada O, Dubrovcakova M, Lakota J
J Cell Mol Med. 2019; 23(5):3641-3655.
PMID: 30916466
PMC: 6484292.
DOI: 10.1111/jcmm.14265.
PKM2 and HIF-1α regulation in prostate cancer cell lines.
Hasan D, Gamen E, Tarboush N, Ismail Y, Pak O, Azab B
PLoS One. 2018; 13(9):e0203745.
PMID: 30216369
PMC: 6138389.
DOI: 10.1371/journal.pone.0203745.
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Wang H, Pochampalli M, Wang L, Zou J, Li P, Hsu S
Oncogene. 2018; 38(1):17-32.
PMID: 30072740
PMC: 6755995.
DOI: 10.1038/s41388-018-0414-x.
PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer.
Yasumizu Y, Hongo H, Kosaka T, Mikami S, Nishimoto K, Kikuchi E
Oncotarget. 2018; 9(45):27698-27707.
PMID: 29963230
PMC: 6021245.
DOI: 10.18632/oncotarget.25498.
The Utility of [F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.
Beinat C, Haywood T, Chen Y, Patel C, Alam I, Murty S
Mol Imaging Biol. 2018; 20(6):1015-1024.
PMID: 29736561
DOI: 10.1007/s11307-018-1194-y.
LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2.
Lu J, Chen M, Gao S, Yuan J, Zhu Z, Zou X
Oncol Lett. 2018; 15(4):4358-4364.
PMID: 29541204
PMC: 5835956.
DOI: 10.3892/ol.2018.7843.
Overexpression of PKM2 promotes mitochondrial fusion through attenuated p53 stability.
Wu H, Yang P, Hu W, Wang Y, Lu Y, Zhang L
Oncotarget. 2016; 7(47):78069-78082.
PMID: 27801666
PMC: 5363644.
DOI: 10.18632/oncotarget.12942.
Oxidative stress in prostate hyperplasia and carcinogenesis.
Udensi U, Tchounwou P
J Exp Clin Cancer Res. 2016; 35(1):139.
PMID: 27609145
PMC: 5017015.
DOI: 10.1186/s13046-016-0418-8.